Related Experiment Videos
[Ofloxacin (RU 43280). Clinical study]
Abstract:
Thirty-two patients were treated by ofloxacin on bacteriological documented infections. They were Enterobacterias: n = 15 (MIC less than or equal to 0.06 to 0.5 microgram/ml); Pseudomonas aeruginosa and Acinetobacter: n = 1 (MIC 0.5 and 4 micrograms/ml); Staphylococcus: n = 6 (MIC less than or equal to 0.06 to 4 micrograms/ml); Pneumococcus: n = 1; Mycoplasma: n = 1; Chlamydia psittaci: n = 2; Legionella pneumophila: n = 1; Rickettsias: n = 4 (three mediterranean fevers one query fever). Ofloxacin was given orally from 400 to 800 mg per day (5 to 15 mg/kg/day). It was used alone 26 times and on 6 occasions it was associated with rifampin on 6 staphylococcal infections. On 19 cases it was used after failure or intolerance of initial therapy. Thirty times it was the first antibiotic substance used. Results were good mainly: 1) on nine pneumonitis (enterobacterias: 4; Pneumococcus: 1; Mycoplasma: 1; Chlamydia: 2; Legionella: 1) during a mean duration of twenty days; 2) urinary infections (n:7) provoked by E. coli and Enterobacter cloacae (mean duration: 20 days); 3) 4 osteo-articular-infections (mean duration: 77 days); 4) Rickettsial infections (n:4) during a mean duration of 11 days. Results are particularly noteworthy because patients treated had severe infections: 12 bacteremias, 1 endocarditis and 1 purulent meningitis. None severe adverse effect was observed.
Insights
Ofloxacin demonstrated good efficacy in treating various severe bacterial infections, including pneumonitis and urinary tract infections, with no severe adverse effects observed in 32 patients. This fluoroquinolone antibiotic is a valuable option for complex infections.
Area of Science:
- Infectious Diseases
- Pharmacology
- Microbiology
Context:
- Ofloxacin is a broad-spectrum fluoroquinolone antibiotic.
- Bacteriological documented infections were treated in 32 patients.
- Many patients had severe infections, including bacteremia and meningitis.
Purpose:
- To evaluate the efficacy and safety of ofloxacin in treating various documented bacterial infections.
- To assess ofloxacin's effectiveness as a primary or salvage therapy.
- To document the clinical outcomes and adverse effects of ofloxacin treatment.
Summary:
- Ofloxacin was administered orally (400-800 mg/day) to 32 patients with documented infections.
- Effective outcomes were observed in pneumonitis, urinary tract infections, osteoarticular infections, and rickettsial infections.
- The treatment showed good results in severe cases, including bacteremia and meningitis, with no severe adverse effects.
Impact:
- Ofloxacin is effective for treating a range of severe bacterial infections.
- The antibiotic is well-tolerated, even in complex cases.
- Results support the use of ofloxacin in clinical practice for documented infections.